IMARC Group has recently released a new research study titled “South Korea Digital Therapeutics Market Size, Share, Trends and Forecast by Application, End Use, and Region, 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.
Market Overview
The South Korea digital therapeutics market size was valued at USD 134.90 Million in 2024 and is projected to reach USD 737.78 Million by 2033, growing at a CAGR of 18.52% during the forecast period 2025-2033. This growth is driven by the government’s aggressive push for digital health innovations through strategic policies, rising chronic and mental health disease burden, and high digital literacy supported by advanced infrastructure.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
South Korea Digital Therapeutics Market Key Takeaways
- Current Market Size: USD 134.90 Million (2024)
- CAGR: 18.52%
- Forecast Period: 2025-2033
- The government of South Korea is aggressively promoting digital health innovation via policies and investments, including the Digital New Deal and the Digital Medical Products Act (DMPA) implemented in January 2024.
- The rising prevalence of chronic diseases such as diabetes, hypertension, cardiovascular conditions, and mental health disorders is accelerating demand for scalable digital therapeutics.
- South Korea's advanced digital infrastructure and high technology adoption rates foster rapid market expansion.
- Digital therapeutics are increasingly embraced by healthcare providers for long-term patient engagement and remote monitoring.
- Regulatory bodies like the Ministry of Food and Drug Safety (MFDS) provide simplified approval pathways, encouraging market entry.
Sample Request Link: https://www.imarcgroup.com/south-korea-digital-therapeutics-market/requestsample
Market Growth Factors
The South Korean government is a major catalyst for the digital therapeutics market, promoting innovation aggressively through focused policies and strategic investments. Initiatives like the Digital New Deal prioritize integrating advanced technologies into healthcare, supported by regulatory bodies such as the Ministry of Food and Drug Safety (MFDS), which has launched simplified approval mechanisms directly targeting digital therapeutics. The 2024 implementation of the Digital Medical Products Act (DMPA) also ensures safety and efficacy of digital health solutions while fostering innovation. Public-private collaborations and pilot initiatives further strengthen the ecosystem, boosting clinical adoption and attracting both local and international industry players.
The increasing burden of chronic diseases and mental health disorders is fueling demand for digital therapeutics. South Korea faces a rising incidence of diabetes, hypertension, cardiovascular diseases, depression, anxiety, and insomnia. Lifestyle factors such as aging population, sedentary habits, and dietary changes contribute to these trends. Digital therapeutics offer customized, evidence-based, non-invasive treatments that patients prefer due to convenience and anonymity, especially for mental health. Healthcare professionals are utilizing these solutions for remote patient interaction and monitoring, aiding long-term disease management and improving quality of life.
Technological advancements and high digital literacy are accelerating market growth. South Korea boasts one of the highest smartphone penetration rates and ultra-fast internet connectivity, enabling widespread adoption of mobile health solutions. Local technology firms are innovating AI-based diagnostics, smart wearables, and cloud therapy platforms that enhance digital therapeutic capabilities. Strengthened data protection and cybersecurity measures increase user trust. An example of technological integration is the 2024 recommendation by Asan Medical Centre (AMC) of VIVID Brain, a virtual reality-based therapy for stroke-related visual deficits, demonstrating personalization and progress tracking in treatment.
Market Segmentation
Application Insights:
- Diabetes: Customized digital therapeutics addressing diabetes management through evidence-based mobile applications and connected platforms.
- Obesity: Digital treatments targeted at weight management incorporating behavioral and lifestyle modifications.
- CVD: Therapeutic tools for cardiovascular disease management leveraging mobile health technology.
- CNS Disease: Digital solutions tailored for central nervous system disorders enhancing patient outcomes.
- Respiratory Diseases: Applications focusing on respiratory health improvements through digital therapy.
- Smoking Cessation: Programs designed to aid quitting smoking via digital interventions.
- Others: Additional digital therapeutics applications addressing various health conditions.
End Use Insights:
- Patients: Primary users receiving digital therapeutic treatments directly.
- Providers: Healthcare professionals incorporating digital therapeutics in patient care.
- Payers: Insurance and reimbursement entities involved in funding treatments.
- Employers: Organizations facilitating employee health through digital interventions.
- Others: Other end users engaging with digital therapeutics.
Ask For an Analyst- https://www.imarcgroup.com/request?type=reportid=39929flag=C
Regional Insights
The South Korea digital therapeutics market covers major regions including Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and others. The report does not provide specific market share or CAGR values by region. The comprehensive regional analysis highlights the importance of these key areas in the overall market dynamics.
Recent Developments News
In 2024, Asan Medical Centre (AMC) began recommending VIVID Brain, a digital therapy leveraging virtual reality and mobile app technology for patients with stroke-induced visual deficits. This 12-week therapy includes personalized training levels based on visual perception assessments, showcasing South Korea’s integration of advanced digital therapeutics in clinical practice.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
